Resumo

TEJEDOR-TEJADA, E; JURADO-HERRERA, S  e  GOMEZ-NUNEZ, MR. Rituximab in combination with hemostatic "bypass" agents for hemophilia acquired with an inhibitor, in the event of a case. Rev. OFIL·ILAPHAR [online]. 2021, vol.31, n.4, pp.433-434.  Epub 19-Set-2022. ISSN 1699-714X.  https://dx.doi.org/10.4321/s1699-714x20210004000020.

Acquired hemophilia is a bleeding disorder caused by the body's own antibodies to factor VIII. It has an estimated incidence of 1-1.5 cases/million/year, with a predominance of elderly subjects. It is considered a rare disease but its impact may be underestimated due to the lack of adequate records, the lack of knowledge by the specialists and its complexity in diagnosing it. There is no fixed protocol in the management of the pathology, so the majority of recommendations are based on the opinions of experts in the treatment of other coagulopathies.

Palavras-chave : Hemophilia A; blood; rituximab; antibodies; immunologic factors; therapeutic use; factor VIII; antagonists & inhibitors.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )